WO2025087431 - PAN-KRAS INHIBITOR AND USE THEREOF IN MEDICINES
National phase entry:
Publication Number
WO/2025/087431
Publication Date
01.05.2025
International Application No.
PCT/CN2024/127637
International Filing Date
28.10.2024
Title **
[English]
PAN-KRAS INHIBITOR AND USE THEREOF IN MEDICINES
[French]
INHIBITEUR PAN-KRAS ET SON UTILISATION DANS DES MÉDICAMENTS
[Chinese]
泛-KRAS抑制剂及其在医药上的应用
Applicants **
BETTA PHARMACEUTICALS CO., LTD
Inventors
WU, Wenmao
DING, Lieming
LI, Shusen
ZHAO, Zhichang
ZHANG, Zhan
WANG, Wei
LI, Boyan
TIAN, Kai
ZHU, Xiaoguan
YANG, Xiang
ZHOU, Yuzhen
WU, Hao
WANG, Jiabing
LAN, Hong
ZHOU, Quan
Priority Data
202311405853.9
27.10.2023
CN
202311543631.3
20.11.2023
CN
202311863699.X
29.12.2023
CN
202410034527.X
10.01.2024
CN
202410145027.3
01.02.2024
CN
202410468223.4
18.04.2024
CN
202410644373.6
22.05.2024
CN
202410748871.5
11.06.2024
CN
202411471487.1
21.10.2024
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 4585 | |
| EPO | Filing, Examination, Granting | 30408 | |
| Japan | Filing, Examination, Granting | 2945 | |
| South Korea | Filing, Examination, Granting | 4077 | |
| USA | Filing, Examination, Granting | 10140 |
Total:
52,155
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present invention relates to a compound of formula (I), or a stereoisomer, a tautomer, a deuterated compound or a pharmaceutically acceptable salt thereof, a preparation method therefor, a pharmaceutical composition comprising the compound, and the use thereof as a drug for treating and/or preventing KRAS-mediated diseases.[French]
La présente invention concerne un composé de formule (I), ou un stéréoisomère, un tautomère, un composé deutéré ou un sel pharmaceutiquement acceptable de celui-ci, son procédé de préparation, une composition pharmaceutique comprenant le composé, et son utilisation en tant que médicament pour le traitement et/ou la prévention de maladies médiées par KRAS.[Chinese]
本发明涉及式(I)所述化合物，或其立体异构体、互变异构体、氘代物或药用盐其制备方法，含有该化合物的药用组合物，及其作为治疗和/或预防由KRAS介导的疾病的药物中的应用。